JCDSA  Vol.6 No.2 , May 2016
Efficacy and Safety of Tinefcon&reg Tablets in Subjects with Plaque Psoriasis: An Open Label, Non-Comparative, Multicenter, Phase IV Trial
Abstract: Importance: This post-marketing surveillance study was conducted to evaluate real-world information about the efficacy and safety of oral Tinefcon? tablets (Sphaeranthus indicus based) in plaque psoriasis patients. Materials and Methods: Patients aged at least 18 years and older with clinical diagnosis of plaque psoriasis, were enrolled in this open label, non-comparative, multicenter trial. All eligible subjects received four 700 mg Tinefcon? tablets/day for 12 weeks. The primary outcome measure was percent change in Psoriasis Area Severity Index (PASI) score from baseline to week 12. The secondary outcome measures were Physician Global Assessment (PGA), Nail Psoriasis Severity Index (NAPSI), Psoriatic Arthritis Evaluation and Gene Expression Profiling and Immunohistochemistry. Results: After completion of Tinefcon? treatment at 12 weeks, more than half of subjects (52%) achieved PASI 50 response; PASI 75 response was attained in 68 (23%) subjects and PASI 90 response in 22 (7%) subjects. Five subjects with severe psoriasis achieved PASI 90 without receiving any concomitant medication. Reduction in severity as assessed by PGA was observed in more than half of patients with moderate disease. Histopathological evaluation revealed that epidermal thickness was considerably reduced in 66% of subjects. The expression of inflammatory marker S100A9 protein was(meaningfully reduced in 60% patients with non-significant reduction of Keratin 10 protein expression. Gene expression analysis showed increase down regulation of SERPINB4; PI3 and KRT16 genes after a 12-week treatment period in subjects with higher PASI scores. Conclusion: Oral Tinefcon? tablets showed good efficacy and had a favorable safety profile in plaque psoriasis patients.
Cite this paper: Sharma, S. , Bhatia, K. , Agarwal, M. , Gupta, S. , Budamakuntla, L. , Grandhi, S. , Titarmare, V. , Pande, S. , Rawal, R. , Samarth, A. , Haq, R. , Saoji, V. , Pratap, D. , Kansal, L. , Saple, D. , Sahay, S. , Kalyani, P. , Goyal, P. , Patil, S. , Kanwar, A. , Swarnakar, B. , Kulkarni, S. , Morde, A. , Khandagale, H. , Dound, Y. , Jadhav, N. , Hegde, S. , Padigaru, M. and Suthar, A. (2016) Efficacy and Safety of Tinefcon&reg Tablets in Subjects with Plaque Psoriasis: An Open Label, Non-Comparative, Multicenter, Phase IV Trial. Journal of Cosmetics, Dermatological Sciences and Applications, 6, 55-66. doi: 10.4236/jcdsa.2016.62008.

[1]   van den Berg, W.B. and McInnes, I.B. (2013) Immunopathogenesis of Psoriasis: Emphasis on the Role of Th17 Cells. Seminars in Arthritis and Rheumatism, 43, 158-170.

[2]   Sivamani, R.K., Correa, G., Ono, Y., Bowen, M.P., Raychaudhuri, S.P. and Maverakis, E. (2010) Biological Therapy of Psoriasis. Indian Journal of Dermatology, 55, 161-170.

[3]   Gottlieb, A.B., Chao, C. and Dann, F. (2008) Psoriasis Comorbidities. Journal of Dermatological Treatment, 19, 5-21.

[4]   Rahman, M., Alam, K., Ahmad, M., Gupta, G., Afzal, M., Akhter, S., et al. (2012) Classical to Current Approach for Treatment of Psoriasis: A Review. Endocrine, Metabolic & Immune Disorders Drug Targets, 12, 287-302.

[5]   Papp, K.A. (2006) The Long-Term Efficacy and Safety of New Biological Therapies for Psoriasis. Archives of Dermatological Research, 298, 7-15.

[6]   Jullien, D., Prinz, J.C. and Nestle, F.O. (2015) Immunogenicity of Biotherapy Used in Psoriasis: The Science Behind the Scenes. Journal of Investigational Dermatology, 135, 31-38.

[7]   Singh, K.K. and Tripathy, S. (2014) Natural Treatment Alternative for Psoriasis: A Review on Herbal Resources. Journal of Applied Pharmaceutical Science, 4, 114-121.

[8]   Galani, V.J., Patel, B.G. and Rana, D.G. (2010) Sphaeranthus indicus Linn.: A Phytopharmacological Review. International Journal of Ayurveda Research, 1, 247-253.

[9]   Jain, A. and Basal, E. (2003) Inhibition of Propionibacterium Acnes-Induced Mediators of Inflammation by Indian Herbs. Phytomedicine, 10, 34-38.

[10]   Ramachandran, S. (2013) Review on Sphaeranthus indicus Linn. (Kottaikkarantai). Pharmacognosy Review, 7, 157-169.

[11]   Chakrabarti, D., Suthar, A., Jayaraman, G., Muthuvelan, B., Sharma, S. and Padigaru, M. (2012) NPS31807, a Standardized Extract from Sphaeranthus indicus, Inhibits Inflammatory, Migratory and Proliferative Activity in Keratinocytes and Immune Cells. Pharmacology & Pharmacy, 3, 178-194.

[12]   Frediksson, T. and Pettersson, U. (1978) Severe Psoriasis—Oral Therapy with a New Retinoid. Dermatologica, 157, 238-244.

[13]   Lee, Y., Jang, S., Min, J.K., Lee, K., Sohn, K.C., Lim, J.S., et al. (2012) S100A8 and S100A9 Are Messengers in the Crosstalk between Epidermis and Dermis Modulating a Psoriatic Milieu in Human Skin. Biochemical and Biophysical Research Communications, 423, 647-653.

[14]   Benoit, S., Toksoy, A., Ahlmann, M., Schmidt, M., Sunderkotter, C., Foell, D., et al. (2006) Elevated Serum Levels of Calcium-Binding S100 Proteins A8 and A9 Reflect Disease Activity and Abnormal Differentiation of Keratinocytes in Psoriasis. British Journal of Dermatology, 155, 62-66.

[15]   Mommers, J.M., van Rossum, M.M., van Erp, P.E. and van De Kerkhof, P.C. (2000) Changes in Keratin 6 and Keratin 10 (co-) Expression in Lesional and Symptomless Skin of Spreading Psoriasis. Dermatology, 201, 15-20.

[16]   Gottlieb, A.B., Matheson, R.T., Lowe, N., Krueger, G.G., Kang, S., Goffe, B.S., et al. (2003) A Randomized Trial of Etanercept as Monotherapy for Psoriasis. Archives of Dermatology, 139, 1627-1632.

[17]   Kim, I.H., West, C.E., Kwatra, S.G., Feldman, S.R. and O’Neill, J.L. (2012) Comparative Efficacy of Biologics in Psoriasis: A Review. American Journal of Clinical Dermatology, 13, 365-374.

[18]   Foell, D. and Roth, J. (2004) Proinflammatory S100 Proteins in Arthritis and Autoimmune Disease. Arthritis and Rheumatism, 50, 3762-3771.

[19]   Gottlieb, A.B., Chamian, F., Masud, S., Abello, M.V., Lowes, M.A., Chen, F., et al. (2005) TNF Inhibition Rapidly Down-Regulates Multiple Proinflammatory Pathways in Psoriasis Plaques. Journal of Immunology, 175, 2721-2729.

[20]   Hedstrom, L. (2002) Serine Protease Mechanism and Specificity. Chemical Reviews, 102, 4501-4524.

[21]   Sivaprasad, U., Kinker, K.G., Ericksen, M.B., Lindsey, M., Gibson, A.M., Bass, S.A., et al. (2015) SERPINB3/B4 Contributes to Early Inflammation and Barrier Dysfunction in an Experimental Murine Model of Atopic Dermatitis. Journal of Investigational Dermatology, 135, 160-169.

[22]   Gudjonsson, J.E., Ding, J., Johnston, A., Tejasvi, T., Guzman, A.M., Nair, R.P., et al. (2010) Assessment of the Psoriatic Transcriptome in a Large Sample: Additional Regulated Genes and Comparisons with in Vitro Models. Journal of Investigational Dermatology, 130, 1829-1840.

[23]   Molhuizen, H.O., Zeeuwen, P.L., OldeWeghuis, D., Geurts van Kessel, A. and Schalkwijk, J. (1994) Assignment of the Human Gene Encoding the Epidermal Serine Proteinase Inhibitor SKALP (PI3) to Chromosome Region 20q12→q13. Cytogenetics and Cell Genetics, 66, 129-131.

[24]   Clauss, A., Lilja, H. and Lundwall, A. (2002) A Locus on Human Chromosome 20 Contains Several Genes Expressing Protease Inhibitor Domains with Homology to Whey Acidic Protein. Biochemistry Journal, 368, 233-242.

[25]   Hendriks, A.G.M., van der Velden, H.M.J., Wolberink, E.A.W., Seyger, M.M., Schalkwijk, J., Zeeuwen, P.L., et al. (2014) The Effect of Adalimumab on Key Drivers in the Pathogenesis of Psoriasis. British Journal of Dermatology, 170, 571-580.